Pharma: Other News To Note
Wednesday, September 18, 2013
• Teva Pharmaceutical Industries Ltd., of Petach Tikva, Israel, said the FDA approved Treanda (bendamustine HCl) injection, a new formulation of currently approved Treanda, indicated for use in patients with indolent B-cell non-Hodgkins’ lymphoma that has progressed during or within six months of treatment with Rituxan (rituximab, Biogen Idec Inc. and Roche AG) or a Rituxan-containing regimen and in patients with chronic lymphocytic leukemia. Teva acquired Treanda through its 2011 buyout of Cephalon Inc.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.